ArticlePloS one2025
Effect of repeated intratracheal instillation of incense smoke condensate in mice.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Incense smoke condensate (ISC) can have harmful mutagenic and genotoxic effects. Epidemiological and experimental studies have reported the negative effects of incense use on humans. We investigated the toxicological effects of the incense smoke condensate ISC in a 2-week repeated intratracheal instillation model in mice. Twenty-five male mice were divided into four treatment groups and one control group (n = 5 per group). The treatment groups received daily intratracheal instillations of ISC at doses of 2.5, 5, 10, and 20 mg/kg/day, and the control group received a vehicle control for the duration of the study. Mortality and body weight were recorded during the study period. At the end of the study, all mice were sacrificed and terminal body weight, organ weight, gross findings, total and differential cell counts in the bronchoalveolar lavage fluid (BALF), and histopathological findings were obtained. Lung inflammatory markers were measured using quantitative real-time polymerase chain reaction. The results showed that ISC exposure led to dose-dependent increases in both absolute and relative left lung weights, as well as in the number of total cells, macrophages, and neutrophils in BALF. Furthermore, the ISC significantly elevated the mRNA expression levels of inflammatory markers such as IL-1β, IL-6, TNF-α, and MMP-12 in the lung tissues in a dose-dependent manner. Histopathological analysis revealed significant changes in the lungs, including epithelial hyperplasia, inflammatory cell infiltration, and macrophage aggregation. These findings indicate that ISC induces lung inflammation. The no-observed-adverse-effect level of ISC was determined to be less than 2.5 mg/kg/day in this mouse model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.